



Contact:

Rick Gregory
R.C. Gregory & Co.
860-677-2377

For Immediate Release

**Xcellerex Founder & CTO Parrish Galliher to be Featured
on Panels at BIO 2009 and IBC Single-Use Conference**

Marlborough, MA, April 28, 2009 – Xcellerex, Inc. today announced that Parrish Galliher, Founder and Chief Technology Officer, will be a featured panelist at the upcoming BIO 2009 conference in Atlanta and the IBC Single-Use Conference in LaJolla, California. Xcellerex will also be exhibiting at both events.

Details on the panel discussions:

BIO 2009: May 18-21; Atlanta, Georgia

PANEL 1: A World of Biomanufacturing: Shortages or Global Glut? (Session ID #2702)

DATE/TIME: Monday, May 18, 2009 - 2:00 PM to 3:30 PM B311 - Georgia World Congress Center

Description: A short time ago, biopharma companies bemoaned the manufacturing bottlenecks that slowed drug development and delayed commercialization. Now, between corporate mergers, technological improvements, and the rise of Asian biomanufacturing, the biopharma world may be facing excess capacity. Moreover, geographic and development-stage mismatches between supply and demand may prevent this growing glut from shrinking the costs of biological drugs to world markets. This session brings together representatives from companies large and

small around the world to illuminate the issue and explain how they are tackling the challenges of global biomanufacturing.

Chair: Howard Levine, President & Principal Consultant, BioProcess Technology Consultants

Panelists:

Hubert Scoble, PhD, Vice President Pharma Development, Managing Director Andover Development Site Head, Wyeth Biotech TO&PS Wyeth

Bryan Lawlis, President & CEO, Itero Biopharmaceuticals, Inc.

Narender Dev Mantena, SVP Strategic Development, Biological E. Limited,

Parrish Galliher, Founder and CTO, Xcellerex Inc.

PANEL 2: Manufacturing of Biologics & Drugs: apid Response: How Biodefense is Driving Transformations in Biomanufacturing (Session ID: 2625)

Date/Time: Wednesday, May 20, 2009 - 8:00 AM to 9:30 AM

Description: Biotechnology's growth is spurring major industry efforts to develop new, high efficiency manufacturing platforms to drastically reduce manufacturing scale-up and production times and costs. Less visibly, government, recognizing that such systems are integral to responding rapidly to pandemic or biological threats, has become a major driver of new manufacturing technology as well. In 2007, DARPA launched an ambitious program specifically aimed at developing ultra-fast, new biomanufacturing technologies. This panel will review progress in these efforts and how technology flowing from it has the potential to transform commercial biomanufacturing as well.

Moderator: Anne Montgomery (moderator) Editor in Chief, BioProcess International

Panelists:

Parrish Galliher, Founder and CTO, Xcellerex

Patrick Lucy, Business Leader Dowpharma

Robert Becker, Ph.D., VP business development, VaxInnate

Robert Backer, CEO SAFEC-Pharma

IBC Single-Use & Disposable Applications for Biopharmaceutical Manufacturing:

June 1-3, 2009, LaJolla, CA

Date/Time: Tuesday, June 2, 2009; 2:15pm

TITLE: Open Platform Approaches for Designing and Implementing Fully Disposable Process Trains

DESCRIPTION: One of the emerging challenges in implementing single use or disposable elements into bioprocessing is integrating various elements within the bioprocess train including downstream processing. This section of our panel discussion will focus on Open Platform Design™ as a way to support fully disposable bioprocess trains and increase process efficiency. Open platform is defined as independence of filters, membranes or separation chemistry and allowing interchangeability. It includes fluid handling and bag use: mixing and in-line dilution as part of process train planning.

At 2:45, a follow-on discussion will continue around the topic of "The Challenge of Interchangeability."

Moderator: Peter Latham, President, BioPharm Services US

Panelists:

Jeffery Lee Craig, Global Director, Life Sciences Marketing and Business Development, ATMI LifeSciences

Rachael Fitzgerald, Process Validation Scientist, Manufacturing Sciences, Bristol-Myers Squibb

Parrish Galliher, Founder and Chief Technology Officer, Xcellerex, Inc.

Uwe Gottschalk, Ph.D., Vice President, Purification Technology, Sartorius Stedim Biotech, Germany

Robert Repetto, Director, Global New Technology and Innovation, Wyeth Biotech

Paul W. Sauer, Senior Director, Process Development, OncoMed Pharmaceuticals Inc.

Ran Zheng, Executive Director, Plant Manager, Clinical Operations, Amgen Inc.

XCELLEREX Exhibition Information

BIO 2009: Booth #4811

IBC Single Use: Booth #205

At both events, Xcellerex plans to exhibit its XDR Single-Use Bioreactors and XDM QUAD™ Single-Use Mixing Systems.

For more details, please see <http://www.xcellerex.com/news-xcellerex-events.htm>

About Xcellerex, Inc.

Xcellerex is revolutionizing the way biomolecules are developed, manufactured, and commercialized. The company's unique single-use component technology platform transforms biomanufacturing economics, enabling the development of biotherapeutics and vaccines, and dramatically improving the ability of Xcellerex and its partners to deploy manufacturing capacity. Xcellerex leverages its technology and services platform by: 1) commercializing its FlexFactories™ (complete, turnkey, modular production trains) and XDR™ (unique, single use component bioreactor systems); 2) building a portfolio of proprietary biotherapeutics and vaccines through creative alliances and in licensing; and 3) creatively structuring transactions around FlexFactories, XDRs and its pipeline. Learn more at www.xcellerex.com.

###